LOGIN  |  REGISTER
Amneal Pharmaceuticals
Compass Therapeutics

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

November 17, 2025 | Last Trade: US$586.31 10.67 -1.79

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:

Jefferies Global Healthcare Conference in London
Thursday, Nov. 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET)
The presentation will be webcast live and may be accessed here.

8th Annual Evercore Healthcare Conference
Tuesday, Dec. 2, 2025 at 4:15 P.M. ET
The presentation will be webcast live and may be accessed here.

Piper Sandler 37th Annual Healthcare Conference
Wednesday, Dec. 3, 2025 at 1:30 P.M. ET
The presentation will be webcast live and may be accessed here.

The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page.

About Madrigal

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact

Tina Ventura, This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact

Christopher Frates, This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page